CCCCC4 Therapeutics, Inc.
$2.85+26% 1Y
$2.85
$1.7152 weeks$4.67
CCCC in its own filings
Nothing in CCCC's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
124
Events found in the filings · across 546 filings · the record starts in 2020
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 25, 2026
Most recent filing · Form 8-K
- Record starts
- Sep 2, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- SEC comment-letter activity13 occurrences
- 2025-12-08
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 25, 2026On September 25, 2026, the Company announced new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma ( “RRMM”), as well as preliminary biomarker data from the first two patients in the ongoing Phase 1b trial of …Regulation FD disclosure · Form 8-K
- Aug 11, 2026C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
- Jun 11, 2026On June 11, 2026, the Company posted on its website a poster presentation with further analysis from its fully enrolled Phase 1 trial of cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (“RRMM”), to be presented at the …Regulation FD disclosure · Form 8-K
- May 15, 2026Departure of Principal Accounting Officer On May 12, 2026, C4 Therapeutics, Inc. (the “Company”) determined that Mark Mossler will no longer serve as the Company’s Chief Accounting Officer, effective May 15, 2026.Director or officer change · Form 8-K
- May 12, 2026C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
- Apr 10, 2026The Board approved the By-laws Amendment in response to recent amendments to the Generate Corporation Law of the State of Delaware regarding such forum selection provisions.Charter/bylaw amendment or fiscal-year change · Form 8-K
- Apr 9, 2026On April 8, 2026, C4 Therapeutics, Inc. (“C4T”) entered into a Research Collaboration and License Agreement ( the “License Agreement”) with F. Hoffmann-La Roche Ltd. (“Roche Basel”) and Hoffmann-La Roche Inc. (“Roche US”, and together with Roche Basel, “Roche”) to collaborate on the discovery, development and …Material agreement entered · Form 8-K
- Feb 26, 2026C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights.Earnings release · press release
- Jan 14, 2026C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways.Regulation FD disclosure · press release
- Nov 6, 2025C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights.Earnings release · press release
- Oct 16, 2025On October 16, 2025, C4 Therapeutics, Inc. (the “Company”) posted a presentation with data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…